CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 289 enrolled
Drug / intervention
XT-150 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04124042
NCT04124042Phase 2Completed
CompareCT.gov

A Double-Blind, Placebo-Controlled Assessment of the Tolerability and Efficacy of XT-150 for the Treatment of Moderate to Severe Pain Due to Osteoarthritis of the Knee

Xalud Therapeutics, Inc.·interventional·Posted Oct 11, 2019·Updated Mar 27, 2025

In Brief

A Phase 2 clinical trial evaluating XT-150 and Placebo for Osteoarthritis, Knee. Completed, enrolled 289 participants across 6 sites in 2 countries.

Detailed Summary

This is a Phase 2 safety and efficacy study of XT-150 in adult participants experiencing moderate to severe pain due to osteoarthritis of the knee.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoarthritis, Knee
CountriesAustralia, United States
Collaborators--

Timeline

Phase 2CompletedFinished
2020202120222023202420252026
First PostedOct 11, 2019
Enrollment StartFeb 14, 2020
Primary CompletionApr 26, 2022
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 6.7 years ago

Interventions

XT-150biological

plasmid DNA

Placebodrug

Placebo is a sterile phosphate-buffered saline